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Sjo¨gren syndromeAbstract Primary Sjo¨gren’s syndrome (pSS) is a systemic autoimmune disease with exocrine gland
dysfunction and multi-organ involvement. Recent progress in understanding the pathogenesis of
pSS offers an opportunity to find new biomarkers for the diagnosis and assessment of disease
activity. Screening noninvasive biomarkers from the saliva and tears has significant potential. The
need for specific and sensitive biomarker candidates in pSS is significant. This review aims to
summarize recent advances in the identification of biomarkers of Sjo¨gren syndrome, trying to
identify reliable, sensitive, and specific biomarkers that can be used to guide treatment decisions.Introduction
Primary Sjo¨gren’s syndrome (pSS) is a chronic systemic
inflammatory autoimmune disease characterized by kerato-
conjunctivitis sicca and xerostomia [1]. It may involve the
exocrine glands of the skin, respiratory, urogenital, and digest
tract [2]. Besides, extra-glandular involvement is common,
including synovitis, interstitial lung disease, neuropathy, renal
disease, vasculitis, and auto-immune cytopenias [2]. Activated
B lymphocytes is a hallmark of the disease, which is
characterized by the presence of rheumatoid factor,hypergammaglobulinemia, and autoantibody to Ro/Sjo¨g
ren’s-syndrome-related antigen A (SSA) and La/Sjo¨gren’s-syn
drome-related antigen B (SSB) [3]. Additionally, there is a
6.5-fold increased risk of non-Hodgkin’s lymphoma in pSS,
which is much higher than other autoimmune diseases [4].
Primary SS occurs alone with more restricted symptoms such
as sicca, while secondary SS (eSS) was related to other
autoimmune diseases, having more symptoms of original
disease other than exocrine glands’ dysfunction [2,5].
The non-specific symptoms such as sicca, fatigue, and
arthralgia usually are ignored by patients, leading to delayed
diagnosis, to a mean of 7 years [6]. At diagnosis, pSS patients
are characterized by high titer of antinuclear antibodies and
IgG antibodies that are not specific for this disease but are
shared with other autoimmune diseases such as systemic lupus
erythematosus (SLE) [7]. The labial salivary gland biopsy is
often helpful to diagnose the pSS disease according to revised
2002 American-European criteria [5] and 2012 American
College of Rheumatology (ACR) criteria [8]. However, the
biopsy is an invasive procedure that is not accepted by allnces and
220 Genomics Proteomics Bioinformatics 13 (2015) 219–223patients, and it may delay definitive diagnosis. For these
reasons, noninvasive biomarkers for assessment and diagnosis
of pSS are urgently needed. An ideal biomarker should be non-
invasive, specific to diagnose, sensitive to treatment, or useful
to predict disease development.
Saliva and tears as ideal biomarker resources
Saliva may represent a crucial source containing valuable
biomarkers for local and systemic disease [9]. Saliva meets
the demands of a simple, inexpensive, and non-invasive sam-
pling method, which can be repeated frequently without risks
and discomfort for the individual [10]. The discovery of
saliva-based molecular and immunologic biomarkers enables
the use of saliva to evaluate the presence of disease. Recently,
quantitative proteomics such as two-dimensional gel elec-
trophoresis (2D-GE) or mass spectrometry (MS) technology
have been utilized to identify saliva biomarkers, e.g., hap-
toglobin hp2, zinc a2-glycoprotein, and human calprotectin
in lung cancer [11].
Previous studies have already suggested saliva proteomic
and genomic biomarker candidates for pSS [12], however, a
sensitive and specific biomarker from this fluid source has
not yet been established [13]. The protein profile of saliva is
dominated by a series of highly-abundant proteins, such as
salivary amylase, albumin, and immunoglobulin, which mask
potential low-abundance biomarkers [14]. High-abundance
proteins ideally should be depleted before application of pro-
teomics. Two novel representative biomarkers, profiling and
carbonic anhydrase I (CA-I), have been recently identified
after depletion of high-abundance proteins followed by
2D-GE, quantitative dimethylation liquid chromatography
tandem MS (LC-MS/MS), and Western blot. Profilin showed
an average increase of 3.19-fold and CA-I a decrease of
1.5-fold in patients with pSS, compared to healthy controls
[14]. Profilin was a cytoskeleton actin related protein, involved
in the organization of microfilaments and required in early
embryo development [15], and CA-I was an enzyme involved
in tissue hydration [16]. However, it is still unclear whether
such protein abnormalities have contributed to the pathogen-
esis of pSS. Moreover, the sensitivity and specificity of both
candidates for diagnosing and evaluating the disease activity
were not shown [14]. This study was also limited by the small
sample size (18 pSS vs. 18 healthy controls for discovery, and
10 pSS vs. 10 healthy controls for validation) (Table 1).
A study by Delaleu et al. [17] aimed to explore biomarker
signatures of pSS using a 187-plex beads and antibody-based
capture assay. There was profound increment of interleukin
4 (IL-4), IL-5, and clusterin (P< 0.001) in the salivary pro-
teome of 48 patients with pSS, compared to controls without
pSS including 12 patients with rheumatoid arthritis (RA)
and 12 healthy individuals [17]. IL-4 and IL-5 are cytokines
produced by T helper 2 (Th2) cells, which are associated with
T lymphocyte differentiation and B lymphocyte activation
[18,19], whereas clusterin is implicated in multiple biological
processes including inflammation [20]. IL-4, IL-5, and clusterin
in combination, were suggested as accurate predictors 93.8%
of disease [17] (Table 1). However, quantitative analysis is
absent, further testing and validation of these biomarker
signatures are needed.Tear is another fluid source with potential to yield dis-
criminatory biomarkers for assessment of systemic disease
and has been proposed as a good source of biomarkers for
the diagnosis of SS [21]. Cathepsin S was a cysteine
endopeptidase, which may be involved in antigen presenta-
tion and immunity [22]. Recently, tear cathepsin S activity
was found significantly increased (P< 0.0001) in patients
with SS, compared to patients with other autoimmune dis-
eases (e.g., RA and SLE), patients with nonspecific dry eye
disease, and healthy controls [22]. This study suggests that
tear cathepsin S activity may be a simple and noninvasive
biomarker for the diagnosis and evaluation of SS. However,
there were no differences detected in tear cathepsin S levels
between patients with pSS and those with eSS. Furthermore,
tear cathepsin S activity did not correlate with the serum
levels of anti-Ro/SSA or anti-La/SSB antibodies. It also
failed to distinguish pSS from eSS as pointed out above
[22]. More important, the authors did not give a cutoff value
to diagnose the disease.Interferon type I signature as a valuable pSS
biomarker
Accumulating evidence supports the notion that interferon
(IFN) type I plays an important role in the pathogenesis of
pSS [23–25]. The expression of IFN type I-inducible genes
(IFN type I signature) was increased in the peripheral blood
and salivary glands of patients with pSS [26]. The IFN type I
signature was present in 55% of patients with pSS and over-
expression of IFN type I signature is associated with higher
levels of disease activity and anti-Ro/SSA or anti-La/SSB
autoantibodies [27,28]. Thus, IFN type I is a potential
biomarker for diagnosis and evaluation of disease activity
in pSS [26].
Furthermore, Maria et al. [23] showed that myxovirus-
resistance protein A (MxA) might serve as a biomarker
for IFN type I activity in patients with pSS. The IFN
scores, representative of total IFN type I activity, were
assessed by the expression levels of certain IFN type I signa-
ture genes such as IFI44, IFI44L, IFIT3, LY6E, and MX1 in
CD14+ monocytes by real-time quantitative PCR. They
found that IFN scores significantly correlated with protein
levels of MxA in the monocytes (r= 0.741, P< 0.001)
and in the whole blood (r= 0.764, P< 0.001). Interestingly,
100 lg/L was the cutoff value of MxA by enzyme
immunoassay, MxA< 100 lg/L was suggested as low and
MxA> 100 lg /L as high. They found that MxA levels cor-
related with the European League Against Rheumatism
(EULAR) SS disease activity index (ESSDAI) scores and
clinical laboratory profiles such as the levels of immunoglob-
ulin (IgG, IgA, and IgM) and autoantibody (anti-Ro/SSA,
anti-La/SSB, and rheumatoid factor). Finally, MxA levels
were reduced in patients treated with hydroxychloroquine,
which is reported to reduce IFN type I activity. Therefore,
MxA level might be useful in identifying patients who
respond to hydroxychloroquine therapy [23]. Nonetheless,
this study was also limited by the small sample size (Table 1).
Further study recruiting more patients is needed to
strengthen this finding.
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development in pSS
Patients with pSS are at a greater risk of developing lymphoma
[4]. A recent multicenter study has found clues of lymphoma
that include low complement component 4 (C4), cryoglobu-
lins, anti-La antibodies, and leukopenia. Salivary swelling
and the absence of the above biomarkers provided a negative
predictive value for lymphoma of 98% in patients with
pSS [29].
Furthermore, Tobon et al. [30] showed that Fms-like
tyrosine kinase 3 ligand (Flt-3L) might be associated with
lymphoma in pSS. There were higher levels of Flt-3L in pSS
patients who had a history of lymphoma. More importantly,
levels of Flt-3L were associated with previously-identified risk
markers for lymphoma development, such as presence of pur-
pura and lymphocytopenia, lower levels of C4 and IgM, higher
levels of b2 -microglobulin, and a higher disease activity score.
Furthermore, the Flt-3L levels were increased in the serum up
to 94 months (mean 46 months) before the diagnosis of lym-
phoma. This study has suggested an ideal cutoff value of
Flt-3L (175 pg/ml) for revealing an association with lymphoma
in patients with pSS (44% for sensitivity, 97.5% for specificity,
and 97% for negative predictive value). It is, therefore,
believed that Flt-3L is an ideal biomarker for lymphoma
development in pSS [30].
B cell abnormalities are known to be present in patients
with pSS [2]. The levels of CXC ligand 13 protein (CXCL13),
a B cell homeostatic chemokine, were elevated in serum
(162 ± 184 pg/ml vs. 26.8 ± 22.8 pg/ml, P< 0.0001) and sal-
iva (368 ± 631 pg/ml vs. 26.7 ± 36.8 pg/ml, P= 0.0016) in
patients with pSS, compared to healthy controls using the
enzyme-linked immunosorbent assay (ELISA). They suggested
72.4 pg/ml and 100.3 pg/ml as an elevated level in serum and
saliva, respectively. Another report found that CXCL13 was
also highly expressed in SS mouse models [31]. Neutralization
of CXCL13 ameliorated disease progression in a murine model
[31]. Therefore, CXCL13 seems to be a promising biomarker in
pSS. However, CXCL13 was not exclusively expressed in pSS.
Expression of CXCL13 was also detected in lupus and corre-
lated with lupus disease activity measures [32].Exploring genomic biomarkers for pSS
MicroRNAs (miRNAs) are small non-coding and single-
stranded RNAs that are able to regulate gene expression post-
transcriptionally [33]. miRNAs have been proposed as excellent
salivary biomarker candidates due to their easy isolation and
identification through quantitative PCR [34–36]. Several novel
miRNAs have been described in pSS [34,37–39]. For instance,
expression of miR-146a was significantly increased in pSS
patients compared with healthy controls [39]. In addition,
another 2 miRNAs, miR-768-3p and miR-574, were associated
with minor salivary gland inflammation in 15 patients with
pSS [38].
Although some studies have been accomplished in the
understanding of miRNA in SS [34,37–39], the role of long
non-coding RNAs (lncRNAs) remained uncharacterized. Ice
et al. found significant upregulation of the 2p25.1 lncRNA in
SS patients (P= 3.69  105) compared to healthy controls
222 Genomics Proteomics Bioinformatics 13 (2015) 219–223[40]. Furthermore, this transcript was found highly expressed
in CD4+ and CD8+ T cells, and NK cells [40].
As we know, epigenetic modifications are important to con-
trol gene expression associated with pathogenesis of autoim-
mune disease [35]. Thabet et al. [41] reported that global
DNA methylation was reduced in salivary gland epithelial cells
(SGECs) from SS patients, which was associated with a 7-fold
decrease in the expression of the gene DNMT1, which encodes
the DNA methyltransferase 1, and a 2-fold increase in the
expression of the gene Gadd45a, which encodes the growth
arrest and DNA-damage-inducible protein GADD45 alpha
(GADD45a). This study suggested that SGEC dysfunction in
SS may be partially linked to epigenetic modifications [41],
which, however, is hard to be a biomarker for diagnosing
and predicting the development of disease. Taken together,
whether alterations in ncRNAs or epigenetic modifications
could serve as reliable biomarkers for diagnosis and evaluation
of disease activity of pSS needs further study.Conclusion and perspective
In summary, a number of candidate saliva biomarkers have
been revealed by quantitative proteomics, enabling exploration
of this simple and noninvasive tool to diagnose and evaluate
the pSS. There are strengths and limitations in our included
studies. Totally, different kinds of biomarkers were reported
such as proteins, genes, or miRNAs. The combined studies
using salivary proteomics and microRNA studies may improve
the sensitivity and specificity of biomarker for disease. Unfor-
tunately technical limitations still stand in the way and saliva
biomarkers that have greater sensitivity and specificity for pre-
dicting disease are needed. There were no traditional tests and
validation cohorts in most studies. Given that IFN type I is
likely to be involved in the pathogenesis of pSS, the observa-
tion that whole-blood MxA level correlates with IFN score
and pSS activity and is reduced after treatment, supports
MxA as a useful candidate biomarker to diagnose and assess
activity in patients with pSS. We could explore more novel
biomarkers through the IFN signal pathway. Interestingly,
Flt-3L could serve as a useful marker to predict the risk of lym-
phoma in patients with pSS, with a high specificity and reason-
able sensitivity, as well as a high negative predictive value.
Further study should concentrate on exploring the reliable bio-
marker from saliva using simple methods. It is likely that those
novel biomarkers with utility as diagnosis and assessment tools
for pSS may become a reality in the near future.Competing interests
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